REPL

Replimune Group Inc

17.12

Oct 29 • 1:57 PM ET +1.06 (6.60%)

Healthcare Biotechnology USA Small NASD

Today, 2:27 AMReplimune shows strong early TUDRIQEV launch traction but financial impact has yet to materialize

Peers: CADL IOVA IMCR CGON GNLX ONCY KRYS MRNA ELTX CLLS

| Held by: XBI VTI IWM VXF IWN IBB LFSC VTWO SCHA DWAS

Scroll to Statements

Index	RUT
Market Cap	1.61B
Enterprise Value	1.43B
Income	-271.03M
Sales	0.00M
Book/sh	2.16
Cash/sh	3.27
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	465
IPO	Jul 20, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	7.93
P/C	5.24
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.90
Current Ratio	7.11
Debt/Eq	0.62
LT Debt/Eq	0.60
Option/Short	Yes / Yes

EPS (ttm)	-2.92
EPS next Y	-1.61
EPS next Q	-0.64
EPS this Y	26.58%
EPS next Y	35.26%
EPS next 5Y	-
EPS past 3/5Y	-4.15% -14.11%
Sales past 3/5Y	- -
EPS Y/Y TTM	2.95%
Sales Y/Y TTM	-
EPS Q/Q	39.93%
Sales Q/Q	-
Earnings	Oct 28 BMO
EPS/Sales Surpr.	31.12% -

Insider Own	5.95%
Insider Trans	-3.19%
Inst Own	102.99%
Inst Trans	18.60%
ROA	-71.01%
ROE	-115.80%
ROIC	-82.65%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	34.46%
SMA50	26.78%
SMA200	84.96%
Trades

Shs Outstand	94.81M
Shs Float	88.61M
Short Float	26.14%
Short Ratio	6.41
Short Interest	23.17M
52W High	16.75 2.21%
52W Low	1.50 1041.33%
Volatility	12.18% 7.58%
ATR (14)	1.07
RSI (14)	73.72
Beta	0.99
Rel Volume	1.24
Avg Volume	3.62M
Volume	3,138,604

Perf Week	42.79%
Perf Month	29.31%
Perf Quarter	52.86%
Perf Half Y	566.15%
Perf YTD	76.13%
Perf Year	67.68%
Perf 3Y	26.07%
Perf 5Y	-41.99%
Perf 10Y	-
Recom	1.00
Target Price	21.86
Prev Close	16.06
Price	17.12
Change %	6.60%

ConsensusModerate Buy

Avg. Price Target

$11.43

Implied Upside

-33.2%

Analysts8incl. previous ratings

Rating Distribution5 Buy · 2 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 07, 2026	Upgrade	WWedbush	Neutral → Outperform	$12	-29.9%
Aug 04, 2026	Upgrade	LLeerink Partners	Market Perform → Outperform	$17	-0.7%
Jul 31, 2026	Upgrade	WWedbush	Neutral → Outperform	$12	-29.9%
Jul 31, 2026	Upgrade	CCantor Fitzgerald	Neutral → Overweight
Jun 30, 2026	Upgrade	BBMO Capital Markets	Underperform → Outperform	$16	-6.5%
Jun 26, 2026	Upgrade	JJP Morgan	Neutral → Overweight	$17	-0.7%
May 29, 2026	Upgrade	JJP Morgan	Underweight → Neutral	$8	-53.3%
Apr 13, 2026	Downgrade	WWedbush	Outperform → Neutral	$2	-88.3%
Apr 13, 2026	Downgrade	LLeerink Partners	Outperform → Market Perform	$2	-88.3%
Apr 13, 2026	Downgrade	JJP Morgan	Neutral → Underweight
Apr 13, 2026	Downgrade	JJefferies	Buy → Hold	$2	-88.3%
Apr 13, 2026	Downgrade	HH.C. Wainwright	Buy → Sell
Apr 13, 2026	Downgrade	BBMO Capital Markets	Market Perform → Underperform	$1	-94.2%
Apr 10, 2026	Downgrade	PPiper Sandler	Overweight → Neutral	$4	-76.6%
Nov 03, 2025	Upgrade	BBMO Capital Markets	Underperform → Market Perform	$11	-35.7%
Oct 27, 2025	Upgrade	HH.C. Wainwright	Neutral → Buy	$12	-29.9%
Oct 20, 2025	Upgrade	WWedbush	Neutral → Outperform	$18	+5.1%
Oct 20, 2025	Upgrade	PPiper Sandler	Neutral → Overweight	$13	-24.1%
Oct 20, 2025	Upgrade	LLeerink Partners	Market Perform → Outperform	$13	-24.1%
Oct 20, 2025	Upgrade	JJP Morgan	Underweight → Neutral

Oct-28-26 11:07PM	Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today? (Stocktwits) +23.07% +6.60%
11:02AM	Replimune Beats On A Shrinking Loss, But The TUDRIQEV Launch Is Still Measured In Accounts, Not Revenue (Earnings Whispers)
07:00AM	Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-22-26 10:08AM	Replimune's Narrowing Losses Meet A Skeptical Tape As Pipeline Clarity Takes Center Stage (Earnings Whispers)
08:00AM	Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026 (GlobeNewswire)
04:01PM	Loading…
Oct-01-26 04:01PM	Replimune Announces TUDRIQEV Now Available in the U.S. for Advanced Melanoma (GlobeNewswire)
Sep-28-26 04:02PM	Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1 (Newsfile)
Sep-16-26 05:30AM	Trump Administration Shift Puts This Corner of Biotech Back in Favor (The Wall Street Journal)
Sep-03-26 08:00AM	Replimune to Present at the Cantor Global Healthcare Conference 2026 (GlobeNewswire)
Aug-27-26 04:15AM	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL (PR Newswire)
Aug-26-26 11:13PM	Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? (Stocktwits)
Aug-19-26 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.13%
Aug-17-26 04:46PM	Did You Lose Money Investing in Replimune Group, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About their Rights Against REPL (Newsfile) +6.49%
Aug-14-26 08:00AM	Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-26 09:00AM	GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase (NewMediaWire)
10:31PM	Loading…
Aug-10-26 10:31PM	Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today? (Stocktwits) +13.35%
12:21PM	REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering But, Retail Sees Share Price Unwinding Over Time (Stocktwits)
08:00AM	Replimune Announces Pricing of $150 Million Underwritten Offering (GlobeNewswire)
07:30AM	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights REPL (Business Wire)
Aug-07-26 08:31PM	Replimunes First Commercial Drug ArrivesWith A 2027 Cash Cliff And 2030 Finish Line (Stocktwits) -6.22%
12:36PM	Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling. (Barrons.com)
Aug-06-26 10:40PM	Why Did IOVA, REPL, ROKU Stocks Surge To 52-Week Highs Today? (Stocktwits) +8.71%
05:37PM	REPL Stock Slumps 11% After-Hours Whats Driving The Selloff? (Stocktwits)
04:00PM	Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen (GlobeNewswire)
Aug-04-26 09:37AM	Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls (The Fly)
06:44AM	Replimunes Melanoma FDA Decision Pending: This Analyst Sees 40% Upside, High Conviction For Approval (Stocktwits)
Aug-02-26 11:17PM	Why Did REPL, SNOW, NET Stocks Surge To 52-Week Highs Last Week? (Stocktwits)
Jul-31-26 09:46AM	Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls (The Fly) +107.02%
08:37AM	This Biotech Stock Is Soaring 132% After Key FDA Vote on Skin Cancer Treatment (Barrons.com)
06:45AM	REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimunes Melanoma After Overwhelmingly Positive Panel Outcome (Stocktwits)
08:14PM	Loading…
Jul-30-26 08:14PM	Why Is REPL Stock Soaring 127% After Hours Today? (Stocktwits)
06:15PM	Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma (GlobeNewswire)
Jul-28-26 06:38PM	REPL Stock Clocks Worst Day In Over 3 Months New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug (Stocktwits) -38.01%
03:31PM	Replimune Is Locked in a Standoff With Regulators. Here Is What It Means for the Stock. (Barrons.com)
01:02PM	Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy (Proactive)
10:55AM	FDA Staff Raise Concerns On Replimunes Skin Cancer Drug REPL Stock Crashes 32% Today Ahead Of Advisory Meeting This Week (Stocktwits)
07:45AM	Nasdaq enters correction as sell-off deepens, while Coke and Sherwin-Williams lead Dow (Proactive)
07:45AM	Dow closes more than 500 points ahead as earnings optimism outweighs tech weakness (Proactive)
Jun-29-26 08:00AM	Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-26-26 08:00AM	Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma (GlobeNewswire)
Jun-19-26 08:24AM	QURE Was Just the Beginning: 5 Biotech Catalysts Im Watching Now (InvestorPlace)
Jun-01-26 06:56AM	Why Is REPL Stock Gaining In Pre-Market Today? (Stocktwits)
May-31-26 08:00AM	Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-30-26 08:00AM	Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-29-26 09:53PM	How Replimune's Drug Got Third Chance After White House Intervention (The Wall Street Journal) +85.68%
10:04AM	REPL Stock Shot Up 80% Today Whats The Deal With FDA? (Stocktwits)
08:00AM	Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA (GlobeNewswire)
07:30AM	Replimune Gets Third Try at FDA Approval After Makary Departure (The Wall Street Journal)
May-20-26 05:30AM	Biotech Investors Are Tuning Out the MAHA Chaos (The Wall Street Journal) +9.79%
May-06-26 06:48PM	Oncolytics Biotech Reports Data in Colorectal Cancer Study (IPO-Edge.com) +19.86%
Apr-27-26 08:00AM	Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +10.74%
Apr-13-26 11:52AM	Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%. (Barrons.com) -64.29%
10:30AM	BC-Most Active Stocks (Associated Press)
09:58AM	Nike downgraded, Starbucks upgraded: Wall Street's top analyst calls (The Fly)
07:42AM	Replimune melanoma therapy rejected by FDA, shares plunge (Proactive)
05:45AM	FDA issues complete response letter to Replimunes RP1 for melanoma (Pharmaceutical Technology)
05:38AM	Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgraded (Investing.com)
Apr-10-26 05:02PM	Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma (GlobeNewswire) -19.46%
12:17PM	Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second Time (Barrons.com)
Mar-10-26 11:31AM	JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer (Zacks)
11:26AM	XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study (Zacks)
Mar-09-26 01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal) +6.94%
Mar-06-26 08:27AM	Mirum Completes Enrollment & Screening in Liver Disease Studies (Zacks) +14.63%
Mar-05-26 12:43PM	Bayer Advances Roundup Settlement With Missouri Court Approval (Zacks)
Mar-04-26 10:36AM	ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M (Zacks)
Mar-03-26 09:55AM	Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect? (Zacks)
05:30AM	MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines (The Wall Street Journal)
Mar-02-26 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire) -6.41%
Feb-12-26 09:55AM	Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know (Zacks)
Feb-03-26 08:00AM	Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +5.81%
Dec-31-25 02:42PM	Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months (Zacks)
Dec-18-25 08:00AM	Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-25 04:45PM	Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025) (GlobeNewswire)
Nov-06-25 08:00AM	Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-22-25 05:47PM	The Best AI for Picking Stocks, Ranked by Performance (MarketBeat)
Oct-20-25 04:10PM	Why Replimune Stock Was Soaring Today (Motley Fool) +98.78% -9.45%
07:00AM	Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma (GlobeNewswire)
Oct-19-25 08:00AM	Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 (GlobeNewswire)
Sep-24-25 11:06AM	REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug (Zacks)
Sep-22-25 05:35AM	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL (PR Newswire)
Sep-19-25 04:08PM	Why Replimune Stock Was Tumbling Again Today (Motley Fool) -6.79%
10:12AM	Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment 'Uncertain' (Insider Monkey)
09:39AM	Intel downgraded, Tesla upgraded: Wall Street's top analyst calls (The Fly)
Sep-18-25 06:59PM	Why Replimune Stock Plummeted by Almost 40% Today (Motley Fool) -39.40%
09:15AM	Replimune Provides Update Following Type A Meeting with FDA (GlobeNewswire)
05:48AM	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL (PR Newswire)
Sep-12-25 04:42PM	Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025 - Contact Levi & Korsinsky (Newsfile)
Sep-04-25 12:56PM	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL (Business Wire)
09:30AM	Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman (PR Newswire)
Sep-03-25 04:18PM	Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman (PR Newswire)
Sep-02-25 08:00AM	Replimune Announces Type A Meeting Scheduled with FDA (GlobeNewswire) +9.26%
Aug-28-25 08:12AM	Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman (Newsfile)
Aug-26-25 08:46AM	Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPL (PR Newswire)
Aug-25-25 09:31AM	Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 (Newsfile)
Aug-20-25 05:04PM	Investors in Replimune Group, Inc. (REPL): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025 (Newsfile) +6.67%
Aug-14-25 04:19PM	Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 (Newsfile) +5.11%
Aug-13-25 03:40PM	Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025 - Contact Levi & Korsinsky (Newsfile)
Aug-12-25 09:00AM	Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REPL (PR Newswire) +5.21%
Aug-11-25 11:01AM	Controversial FDA regulator back 12 days after resigning (Quartz) -5.67%
Aug-07-25 08:00AM	Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VELEKA PEEPLES-DYER	Director	Oct 28 '26	Proposed Sale	12.90	12,000	154,745		Oct 28 04:02 PM
Hill Emily Luisa	Chief Financial Officer	Aug 17 '26	Sale	14.28	9,256	132,176	215,852	Aug 19 06:42 PM
Patel Sushil	Chief Executive Officer	Aug 10 '26	Sale	12.97	39,341	510,253	708,151	Aug 12 05:07 PM
Hill Emily Luisa	Chief Financial Officer	Aug 10 '26	Sale	12.97	11,448	148,481	225,108	Aug 12 05:06 PM
Xynos Konstantinos	Chief Medical Officer	Aug 10 '26	Sale	12.97	11,447	148,468	224,215	Aug 12 05:05 PM
Schwendenman Andrew	Chief Accounting Officer	Aug 10 '26	Sale	12.97	7,632	98,987	99,425	Aug 12 05:04 PM
Sarchi Christopher	Chief Commercial Officer	Jun 01 '26	Sale	9.24	12,000	110,880	180,962	Jun 03 08:30 PM
Xynos Konstantinos	Chief Medical Officer	May 18 '26	Sale	5.08	14,023	71,237	235,662	May 20 04:18 PM
Schwendenman Andrew	Chief Accounting Officer	May 18 '26	Sale	5.08	7,894	40,102	107,057	May 20 04:17 PM
Sarchi Christopher	Chief Commercial Officer	May 18 '26	Sale	5.08	8,626	43,820	192,962	May 20 04:16 PM
Astley-Sparke Philip	Director	May 18 '26	Sale	5.08	17,657	89,698	1,412,414	May 20 04:16 PM
Patel Sushil	Chief Executive Officer	May 18 '26	Sale	5.08	37,324	189,606	747,492	May 20 04:15 PM
Hill Emily Luisa	Chief Financial Officer	May 18 '26	Sale	5.08	7,812	39,685	236,556	May 20 04:15 PM
Sarchi Christopher	Chief Commercial Officer	Apr 02 '26	Sale	8.01	6,500	52,065	151,588	Apr 06 04:30 PM
Christopher Sarchi	Officer	Apr 02 '26	Proposed Sale	7.70	18,500	142,450		Apr 02 04:15 PM
Dhingra Kapil	Director	Dec 09 '25	Option Exercise	1.75	3,169	5,546	3,169	Dec 11 04:30 PM
Dhingra Kapil	Director	Dec 09 '25	Sale	10.40	3,169	32,958	0	Dec 11 04:30 PM
Kapil Dhingra	Director	Dec 09 '25	Proposed Sale	10.38	3,164	32,842		Dec 09 04:00 PM
Patel Sushil	Chief Executive Officer	Dec 02 '25	Sale	11.13	10,000	111,300	333,576	Dec 04 04:30 PM
Sushil Patel	Chief Strategy Officer	Dec 02 '25	Proposed Sale	11.13	10,000	111,303		Dec 02 04:11 PM
Sarchi Christopher	Chief Commercial Officer	Nov 17 '25	Sale	9.10	5,208	47,393	123,088	Nov 19 04:31 PM
Xynos Konstantinos	Chief Medical Officer	Nov 17 '25	Sale	9.10	7,248	65,957	139,685	Nov 19 04:30 PM

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

CEO & DirectorDr. Sushil Patel Ph.D.

Chief Financial OfficerMs. Emily Luisa Hill

M.D.Dr. Konstantinos Xynos M.B.A.

Executive ChairmanMr. Philip Astley-Sparke F.S.A.

Senior Vice President of Quality AssuranceMs. Carolyn Trott

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REPL

Replimune Group Inc

Upgrade your Finviz experience